HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Alpha Tau Medical (NASDAQ:DRTS) and maintained a price target of $9.
August 20, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Alpha Tau Medical and maintained a $9 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Alpha Tau Medical's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100